JP2022537158A5 - - Google Patents
Info
- Publication number
- JP2022537158A5 JP2022537158A5 JP2021573841A JP2021573841A JP2022537158A5 JP 2022537158 A5 JP2022537158 A5 JP 2022537158A5 JP 2021573841 A JP2021573841 A JP 2021573841A JP 2021573841 A JP2021573841 A JP 2021573841A JP 2022537158 A5 JP2022537158 A5 JP 2022537158A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076031A JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861139P | 2019-06-13 | 2019-06-13 | |
| US62/861,139 | 2019-06-13 | ||
| US202062963884P | 2020-01-21 | 2020-01-21 | |
| US62/963,884 | 2020-01-21 | ||
| PCT/US2020/037477 WO2020252294A1 (en) | 2019-06-13 | 2020-06-12 | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076031A Division JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537158A JP2022537158A (ja) | 2022-08-24 |
| JP2022537158A5 true JP2022537158A5 (https=) | 2023-06-16 |
| JPWO2020252294A5 JPWO2020252294A5 (https=) | 2023-06-16 |
Family
ID=71608047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573841A Ceased JP2022537158A (ja) | 2019-06-13 | 2020-06-12 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
| JP2025076031A Pending JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076031A Pending JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200390899A1 (https=) |
| EP (1) | EP3983082A1 (https=) |
| JP (2) | JP2022537158A (https=) |
| KR (1) | KR20220034784A (https=) |
| CN (1) | CN114585390A (https=) |
| AU (1) | AU2020291014B2 (https=) |
| BR (1) | BR112021025034A2 (https=) |
| CA (1) | CA3142887A1 (https=) |
| IL (1) | IL288816A (https=) |
| MX (1) | MX2021015221A (https=) |
| TW (1) | TW202112752A (https=) |
| WO (1) | WO2020252294A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JP2022549510A (ja) * | 2019-09-30 | 2022-11-25 | ボルト バイオセラピューティクス、インコーポレーテッド | アミド結合したアミノベンズアゼピン免疫複合体、及びその使用 |
| CA3155077A1 (en) | 2019-10-25 | 2021-04-29 | Romas Kudirka | Thienoazepine immunoconjugates, and uses thereof |
| IL294818A (en) * | 2020-01-21 | 2022-09-01 | Bolt Biotherapeutics Inc | Anti-pd-l1 antibodies |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| CN115996756A (zh) * | 2020-05-08 | 2023-04-21 | 博尔特生物治疗药物有限公司 | 弹性蛋白酶底物肽连接子免疫缀合物及其用途 |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| CN116234586A (zh) * | 2020-08-13 | 2023-06-06 | 博尔特生物治疗药物有限公司 | 吡唑并氮呯免疫缀合物及其用途 |
| JP2023552791A (ja) * | 2020-12-11 | 2023-12-19 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ｈｅｒ２免疫複合体、及びその使用 |
| CN116635084A (zh) * | 2020-12-11 | 2023-08-22 | 博尔特生物治疗药物有限公司 | 抗cea免疫缀合物和其用途 |
| US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| WO2022125908A1 (en) * | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 immunoconjugates, and uses thereof |
| US20240091370A1 (en) * | 2020-12-11 | 2024-03-21 | Bolt Biotherapeutics, Inc. | Anti-her2 immunoconjugates, and uses thereof |
| EP4277925A4 (en) * | 2021-01-14 | 2025-06-11 | Gritstone bio, Inc. | Multispecific antibodies and methods of use |
| CA3212926A1 (en) * | 2021-03-26 | 2022-09-29 | Gary Brandt | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| CN117940168A (zh) * | 2021-03-26 | 2024-04-26 | 博尔特生物治疗药物有限公司 | 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途 |
| CA3218829A1 (en) * | 2021-05-19 | 2022-11-24 | Zhaolong Tong | Nitrogen-containing compound, conjugate containing said compound, and application thereof |
| CN118475372A (zh) | 2021-10-29 | 2024-08-09 | 博尔特生物治疗药物有限公司 | 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途 |
| WO2023109944A1 (zh) * | 2021-12-16 | 2023-06-22 | 映恩生物制药（苏州）有限公司 | Tlr调节剂及其用途 |
| TW202339806A (zh) * | 2022-02-09 | 2023-10-16 | 美商博特生物治療公司 | ８—磺醯基—苯并氮呯免疫結合物及其用途 |
| CN118843480A (zh) * | 2022-02-09 | 2024-10-25 | 博尔特生物治疗药物有限公司 | 高分子负载的8-磺酰基-苯并氮杂䓬化合物及其用途 |
| TW202411235A (zh) * | 2022-06-02 | 2024-03-16 | 大陸商映恩生物製藥（蘇州）有限公司 | 一種藥物化合物及其用途 |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2399940A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| LT1976880T (lt) | 2005-12-21 | 2016-10-10 | Amgen Research (Munich) Gmbh | Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| PT2740794T (pt) | 2011-08-04 | 2018-06-14 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| PT2818483T (pt) | 2012-02-21 | 2017-10-09 | Toray Industries | Composição medicinal para tratamento e/ou prevenção de cancro |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| RU2646466C2 (ru) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Метод детекции рака |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| ES2704909T3 (es) | 2013-08-09 | 2019-03-20 | Toray Industries | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| EP3233835B1 (en) * | 2014-12-18 | 2019-01-23 | F.Hoffmann-La Roche Ag | Benzazepine sulfonamide compounds |
| KR102581546B1 (ko) * | 2015-03-06 | 2023-09-25 | 에프. 호프만-라 로슈 아게 | 벤즈아제핀 다이카복스아미드 화합물 |
| JP2018532803A (ja) * | 2015-11-02 | 2018-11-08 | ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 癌を処置するためのｔｌｒ８アゴニストの使用 |
| JP6918838B2 (ja) * | 2016-05-23 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| EP3464274B1 (en) * | 2016-05-23 | 2020-05-27 | H. Hoffnabb-La Roche Ag | Benzazepine dicarboxamide compounds with secondary amide function |
| JP7012668B2 (ja) * | 2016-06-12 | 2022-02-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物 |
| KR20240005247A (ko) | 2016-10-28 | 2024-01-11 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| ES2894731T3 (es) * | 2017-03-15 | 2022-02-15 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| WO2019118884A1 (en) * | 2017-12-15 | 2019-06-20 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
| AU2019337654A1 (en) * | 2018-09-12 | 2021-04-08 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| US20200113912A1 (en) * | 2018-09-12 | 2020-04-16 | Silverback Therapeutics, Inc. | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates |
| WO2020056194A1 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
-
2020
- 2020-06-12 AU AU2020291014A patent/AU2020291014B2/en active Active
- 2020-06-12 EP EP20740106.8A patent/EP3983082A1/en active Pending
- 2020-06-12 CA CA3142887A patent/CA3142887A1/en active Pending
- 2020-06-12 MX MX2021015221A patent/MX2021015221A/es unknown
- 2020-06-12 BR BR112021025034A patent/BR112021025034A2/pt unknown
- 2020-06-12 TW TW109119949A patent/TW202112752A/zh unknown
- 2020-06-12 US US16/900,193 patent/US20200390899A1/en not_active Abandoned
- 2020-06-12 CN CN202080053101.9A patent/CN114585390A/zh active Pending
- 2020-06-12 JP JP2021573841A patent/JP2022537158A/ja not_active Ceased
- 2020-06-12 WO PCT/US2020/037477 patent/WO2020252294A1/en not_active Ceased
- 2020-06-12 KR KR1020227001083A patent/KR20220034784A/ko active Pending
-
2021
- 2021-12-09 IL IL288816A patent/IL288816A/en unknown
-
2025
- 2025-05-01 JP JP2025076031A patent/JP2025118748A/ja active Pending
- 2025-05-09 US US19/203,992 patent/US20250263392A1/en active Pending